Levitee Labs Inc.

As of June 30, 2022, Levitee Labs Inc. has 75.82M shares outstanding.

These figures are as of June 30, 2022. The price-to-sales ratio is 0.13, and the price-to-book ratio stands at 0.19.

These figures are as of June 30, 2022. The EV/Sales ratio of 0.48 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative.

As of June 30, 2022, Levitee Labs Inc. maintains a current ratio of 0.45, meaning it holds 0.5x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 59.67, indicating elevated leverage, while an interest coverage ratio of -235.98 demonstrates limited ability to service its debt obligations.

Over the twelve months ended June 30, 2022, Levitee Labs Inc. posted a negative return on equity (ROE) of -133.53, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -89.73, reflecting losses generated across the asset base. Inventory turnover of 5.56 indicates how many times Levitee Labs Inc. sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2022, Levitee Labs Inc. posted a gross margin of 50.58, reflecting its pricing power and cost economics. The operating margin of -134.81 and net profit margin of -143.11 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2022. Free cash flow yield is negative at -578.80: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -1,282.17, meaning Levitee Labs Inc. raised more capital through share issuance and new debt than it returned via dividends and buybacks.

As of June 30, 2022, Levitee Labs Inc. has an Altman Z-Score of -11.50, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.